Literature DB >> 1954073

Relationship between systemic drug absorption and gastrointestinal transit after the simultaneous oral administration of carbamazepine as a controlled-release system and as a suspension of 15N-labelled drug to healthy volunteers.

I R Wilding1, S S Davis, J G Hardy, C S Robertson, V A John, M L Powell, M Leal, P Lloyd, S M Walker.   

Abstract

1. Plasma drug concentrations after a single oral administration of a suspension of carbamazepine (CBZ) and a 20/200 CBZ Oros osmotic pump system were measured in eight healthy male volunteers. The oral suspension contained 100 mg CBZ labelled with the stable isotope nitrogen-15, whilst the Oros contained 200 mg unlabelled CBZ. Plasma concentrations of [15N]-CBZ and CBZ were measured simultaneously by gas chromatography-mass spectrometry. 2. The position of the CBZ Oros (labelled with indium-111) in the gastrointestinal tract was followed by gamma scintigraphy. Plasma drug concentrations after the two treatments were used to relate pharmacokinetic with transit data. 3. The Oros was taken after breakfast and gastric emptying occurred between 1.1- greater than h post-dosing (median, 5.3 h). Small intestinal transit times ranged from 1.5- greater than 3.6 h, with a median of 2.2 h. There were wide individual variations in colonic transit, and the total transit time ranged from 10-60 h (median, 22 h). 4. Relative systemic bioavailability of CBZ from the Oros was reduced compared with that from the suspension (mean dose normalised AUC ratio = 0.69 +/- 0.17; mean dose-normalised AUC ratio = 0.85 +/- 0.13, allowing for actual release from the Oros system). 5. The in vivo absorption of drug into the systemic circulation from the Oros was estimated using the Wagner-Nelson method. This showed that absorption of CBZ was rapid when the Oros was present in the stomach and small intestine, the rate being determined by the release of drug from the system.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1954073      PMCID: PMC1368633          DOI: 10.1111/j.1365-2125.1991.tb03954.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  KINETIC ANALYSIS OF BLOOD LEVELS AND URINARY EXCRETION IN THE ABSORPTIVE PHASE AFTER SINGLE DOSES OF DRUG.

Authors:  J G WAGNER; E NELSON
Journal:  J Pharm Sci       Date:  1964-11       Impact factor: 3.534

2.  Relationship between the rate of appearance of oxprenolol in the systemic circulation and the location of an oxprenolol Oros 16/260 drug delivery system within the gastrointestinal tract as determined by scintigraphy.

Authors:  S S Davis; N Washington; G D Parr; A H Short; V A John; P Lloyd; S M Walker
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

3.  Bioavailability of rectally administered carbamazepine mixture.

Authors:  P J Neuvonen; O Tokola
Journal:  Br J Clin Pharmacol       Date:  1987-12       Impact factor: 4.335

4.  Transit of pharmaceutical dosage forms through the small intestine.

Authors:  S S Davis; J G Hardy; J W Fara
Journal:  Gut       Date:  1986-08       Impact factor: 23.059

5.  Gastric emptying of large single unit dosage forms.

Authors:  S S Davis; F Norring-Christensen; R Khosla; L C Feely
Journal:  J Pharm Pharmacol       Date:  1988-03       Impact factor: 3.765

6.  Drug delivery to the proximal colon.

Authors:  J G Hardy; C G Wilson; E Wood
Journal:  J Pharm Pharmacol       Date:  1985-12       Impact factor: 3.765

7.  Gastrointestinal transit of Oros drug delivery systems in healthy volunteers: a short report.

Authors:  V A John; P A Shotton; J Moppert; W Theobald
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

8.  Bioequivalence of carbamazepine chewable and conventional tablets: single-dose and steady-state studies.

Authors:  K K Chan; R J Sawchuk; T A Thompson; E Redalieu; W E Wagner; A R LeSher; B J Weeks; N R Hall; A Gerardin
Journal:  J Pharm Sci       Date:  1985-08       Impact factor: 3.534

9.  Relative bioavailability of rectally administered carbamazepine suspension in humans.

Authors:  N M Graves; R L Kriel; C Jones-Saete; J C Cloyd
Journal:  Epilepsia       Date:  1985 Sep-Oct       Impact factor: 5.864

10.  Osmotic delivery systems for the beta-adrenoceptor antagonists metoprolol and oxprenolol: design and evaluation of systems for once-daily administration.

Authors:  F Theeuwes; D R Swanson; G Guittard; A Ayer; S Khanna
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

  10 in total
  8 in total

Review 1.  Gamma scintigraphy in the evaluation of pharmaceutical dosage forms.

Authors:  S S Davis; J G Hardy; S P Newman; I R Wilding
Journal:  Eur J Nucl Med       Date:  1992

Review 2.  Factors influencing the bioavailability of peroral formulations of drugs for dogs.

Authors:  S Sabnis
Journal:  Vet Res Commun       Date:  1999-11       Impact factor: 2.459

Review 3.  Pharmacokinetic variability of long-acting stimulants in the treatment of children and adults with attention-deficit hyperactivity disorder.

Authors:  James C Ermer; Ben A Adeyi; Michael L Pucci
Journal:  CNS Drugs       Date:  2010-12       Impact factor: 5.749

Review 4.  Novel oral drug formulations. Their potential in modulating adverse effects.

Authors:  A T Florence; P U Jani
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

Review 5.  Applications of stable isotopes in clinical pharmacology.

Authors:  Reinout C A Schellekens; Frans Stellaard; Herman J Woerdenbag; Henderik W Frijlink; Jos G W Kosterink
Journal:  Br J Clin Pharmacol       Date:  2011-12       Impact factor: 4.335

Review 6.  Pharmacokinetic considerations in gastrointestinal motor disorders.

Authors:  G S Hebbard; W M Sun; F Bochner; M Horowitz
Journal:  Clin Pharmacokinet       Date:  1995-01       Impact factor: 6.447

7.  Stable isotope methodology for studying the performance of metoprolol Oros tablets in comparison to conventional and slow release formulations.

Authors:  J Richard; J M Cardot; J Godbillon
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1994 Oct-Dec       Impact factor: 2.441

Review 8.  Extended-release formulations for the treatment of epilepsy.

Authors:  Meir Bialer
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.